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Fragile X-associated Tremor Ataxia Syndrome (FXTAS) is a neurodegenerative disease that 
results from a CGG repeat expansion in the 5’UTR of FMR1. Pathogenesis in FXTAS is thought 
to involve a dominant RNA gain of function mechanism, whereby the CGG repeat mRNA binds 
to and sequesters specific RNA binding proteins. However, our group has recently discovered 
that the repeats are also capable of eliciting aberrant translation initiation in the 5’UTR in the 
absence of an AUG start codon (RAN translation), leading to the production of a polyglycine-
containing protein that forms ubiquitinated aggregates in cells and animal models.  A critical 
question that emerges from this work is whether this polyglycine protein contributes directly to 
toxicity, or whether the neurodegeneration is mediated strictly via RNA toxic mechanisms. To 
investigate this question, we created strains of drosophila that decouple the potential CGG RNA 
and protein mediated toxic products. This was achieved by placing the CGG repeat in either the 
5’UTR or 3’UTR of a heterologous gene, eGFP. Placement in the 3’UTR precludes RAN 
translation. To enhance the protein mediated toxic effects, we have inserted an AUG start codon 
5’ to the repeat, which leads to increased production of the polyglycine protein. As previously 
reported, expression of a (CGG)100 repeat in the 5’UTR of eGFP leads to a modest rough eye 
phenotype with isolated oomatidial expression and a decrease in viability with ubiquitous 
expression compared to control flies. In lines where the CGG repeat is in the 3’UTR of eGFP, 
there is very little overt oomatidial degeneration and no effect on viability. In contrast, flies with 
an ATG codon inserted 5’ to the repeat, exhibit an enhanced degenerative eye phenotype and 
further reduced viability compared to flies lacking this ATG. These studies support a model 
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Repeat Expansion Neurodegenerative Disorders 
At least 22 neurodegenerative diseases can be linked back to aberrant expansions within 
stretches of DNA, despite the relatively recent discovery of microsatellite regions within DNA.  
Repeat expansion diseases are currently classified into three main categories by their mechanism 
of action: diseases in which the expansion elicits a loss of expression; those in which exonic 
repeat expansions result in altered protein function; and a final category in which non-coding 
RNA elicit a toxic gain of function. 
Repeat expansions that trigger a loss of function by eliciting changes in the local chromatin 
structure surrounding the repeat, leading to transcriptional silencing of the associated gene.  Two 
examples of this subset are Fragile X Syndrome and Friedreich’s Ataxia (FRDA); FXS results 
from the loss of FMRP, and FRDA from the reduced expression of frataxin (Campuzano, 1996).  
The loss of these proteins as the cause of disease is supported by rare cases of FXS and FRDA 
that are caused by point mutations rather than repeat expansions (Wang, 1997; McCormack, 
2000).   In FXS, the expansion of 200 or more repeats leads to hypermethylation at the site of 
FMR1, which then leads to transcriptional silencing and greatly lessened production of FMRP 
(Sutcliff, 1992).  Similarly, FRDA results from a GAA repeat expansion in an intronic region of 
FXN, a gene that encodes the protein frataxin (Campuzano, 1997).  In both of these disorders, the 
resulting symptoms can be traced to the loss of the target protein--cognitive dysfunction seen in 
FXS is resultant of loss of the synaptically-expressed FMRP, and the degeneration in 
Friedreich’s ataxia is due to the disruption of frataxin’s interaction with mitochondria and iron-
sulfur clusters.  Ultimately, while the mechanism of transcriptional silencing is similar between 
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diseases in this subset, the symptoms are unique and completely dependent on loss of the 
affected protein.  
In contrast, exonic repeat expansions are inherited in a dominant fashion, suggesting that they 
elicit a dominant gain of function toxicity rather than haploinsufficiency.  These repeats are 
coded into proteins homopolymeric protiens, typically polyglutamine.  There are 9 
polyglutamine expansion diseases, including Huntington’s disease, Kennedy’s disease (spinal 
and bulbar muscular atrophy), Dentatorubropallidoluysian Atrophy (DRPLA) and six different 
spinocerebellar ataxias.  An additional repeat expansion disorder, oculopharyngeal muscular 
dystrophy (OPMD) results from a polyalanine expansion in the TATA binding protein.  These 
homopolymeric protein expanions can elicit a toxic gain of function through a number of 
different mechanisms; the build-up of protein aggregates, transcriptional dysregulation, and 
neuronal processes such as mitochondrial dysfunction have all been implicated in the 
pathogenesis of these diseases.  Polyglutamine proteins are very aggregate-prone, leading to the 
formation of insoluble inclusions, the contribution of which to disease is not fully determined 
(Scherzinger 1997).  Studies have been done correlating aggregate formation to increased 
susceptibility of cell death, through mechanisms of oxidative stress or impairment of the UPS 
(Hackman 1998); however, other studies have indicated that aggregates could potentially be a 
protective mechanism, as some results show an inverse correlation between cell survival and 
propensity to form aggregates (Bowman 2005).  
 Transcriptional dysregulation is also a potential mechanism for polyglutamine disease toxicity, 
postulating that the proteins, both in aggregate form and in soluble monomeric form, could 
interact with transcription factors and transcription machinery in a way that disrupts 
transcriptional stability of the cells (Gatchel 2005).  For example, in Huntington’s disease, 
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mutant huntingtin has been shown to recruit important transcription factors such as TBP into 
inclusions both in vitro and in post mortem samples; likewise, CBP has been found in inclusions 
in SMBA cell models (Cha 2000).  Aberrant proteins are also implicated in a disruption of 
normal cellular processes such as mitochondrial dysfunction and apoptosis.  For example, mutant 
huntingtin disrupts calcium homeostasis and mitochondrial function, and the cleavage of 
polyglutamine proteins by calpain and caspases can produce toxic protein fragments (Tang 
2005). 
However, not all repeats fit easily into these two categories.  A third class of repeat expansion 
disorders contain repeats in putatively non-exonic gene regions but are inherited in a dominant 
fashion.  After early studies failed to demonstrate a role for haploinsufficiency in pathogenesis, it 
became clear that the repeat expansions are capable of eliciting a toxic gain of function as RNA.  
A number of degenerative diseases, such as DM1, have been explained by this RNA gain of 
function theory, which suggests that the non-coding RNA disrupts cellular metabolism through 
sequestration of critical proteins within the cell.  The sequestration of these RNA binding 
proteins leads to a loss of their normal function, causing dysregulation of RNA splicing and 
maturation events, and improperly produced downstream proteins.  In addition to aberrant 
splicing, repeat RNA is also found within inclusions in these diseases, along with protein 
degradation machinery, another possible mechanism of toxicity.  There is a good deal of 
evidence to support alternate splicing as the disease-causing mechanism in myotonic dystrophy.  
Evidence supporting this includes the finding that mouse lines in which MBNL has been 
knocked out develop myotonia at around 6 weeks old, and that a number of mRNAs are 
alternatively spliced, including troponin, insulin receptor, and CIC-1 (Kanadia, 2003).  This 
same group then found that the overexpression of MBNL in a poly(CUG) model of myotonic 
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dystrophy lead to the reversal of myotonia and missplicing (Kanadia, 2006).  This data gives 
support to the theory that myotonic dystrophy arises from sequestration of MBNL and the 
resulting aberrant splice patterns of its target RNA.  Some evidence suggests that FXTAS 
pathogenesis is analogous to that of myotonic dystrophy.  For example, evidence suggests that 
Sam68, an RNA binding protein, associates with CGG repeat inclusions, resulting in aberrant 
splicing of several RNAs (Sellier, 2010).  These aberrantly spliced RNAs include Bcl-xl, SMN2, 
and ATP11B, which have been found to be aberrantly spliced in FXTAS patients as well (Sellier, 
2010).    
 
Fragile X Tremor/Ataxia Syndrome 
Fragile X Tremor/Ataxia Syndrome (FXTAS) is a neurodegenerative disease related to Fragile X 
Syndrome (FXS), the most prevalent cause of inherited cognitive impairment, causing severe 
intellectual disability in roughly 1 in every 1 500 males (Rousseau 1991).  Fragile X Syndrome 
results from the loss of Fragile X Mental Retardation Protein (FMRP), when the gene becomes 
hypermethylated due to a CGG expansion in the 5’-UTR region of FMR1.  FMRP is an RNA 
binding protein that is produced at synapses, and its down-regulation leads to mental retardation, 
emotional disorders, and some stereotypic physical features.  Individuals with FXS typically 
have a CGG expansion that is greater than 200 repeats (Hagerman RJ, 1999).   
In contrast to FXS, FXTAS result from a premutation--a CGG expansion over 55 repeats long, 
but under the 200 repeats (RJ Hagerman 2001).  Rather than impacting an individual 
developmentally, FXTAS operates as a neurodegenerative disease, affecting approximately 1 in 
3000 men over the age of 50 worldwide (Jacquemont 2004).  Due to its location on the X-
chromosome, FXTAS is primarily found in males and tends to be more severe in males, as the 
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presence of another X-chromosome with a normal repeat expansion will produce the correct 
amount of FMRP (Jin 2000).   
FXTAS pathology is characterized by a number of neurologic and cognitive abnormalities; most 
commonly, a progressive intention tremor, gait ataxia, and dementia.  Less frequently, patients 
can experience parkinsonism, peripheral neuropathy, autonomic dysfunction, and cognitive and 
emotional disturbances (Greco 2006).  These clinical symptoms are associated with 
neuropathologic changes including  cortical and subcortical atrophy, and spongiosis of cerebellar 
and cerebral white matter (Greco 2002, Brunberg 2002).  Another constant feature of FXTAS is 
the presence of ubiquitin positive inclusions in neurons and astrocytes throughout the cortex and 
deep cerebellum; interestingly, the number of these inclusions correlates with repeat  
length(Greco 2006).  
 
Molecular Pathology of FXTAS 
The differences in phenotype between FXS and FXTAS suggest that, though related, the two 
diseases must operate under two distinct molecular mechanisms of pathogenesis.  The initial 
pathological cause of FXTAS is the presence of a CGG premutation that is not methylated, and 
does not initially cause significant mental impairment developmentally.  The CGG premutation 
is unstable, and is prone to expand inter-generationally with maternal transmission; indeed, this 
expansion is how FXS is passed down from a mother with a premutation to her son (Jin 2000).  It 
is thought that the CGG expansion is able to form a hairpin structure. 
In contrast to FXS, pre-mutation repeat expansions do not silence the FMR1 gene--rather, they 
actually trigger an over-production of FMR1 mRNA, resulting from the non-methylated repeat 
and chromatin alterations. Despite this overproduction of FMR1 mRNA, there are still  normal to 
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slightly reduced levels of FMRP, suggesting that FXTAS pathogenesis is not entirely due to 
insufficient amounts of FMRP (Garcia-Arocena 2010).  
The elevated levels of FMR1 mRNA suggested early on that FXTAS might result from a CGG 
repeat RNA gain of function toxicity as the primary cause of neurodegeneration.  Evidence of 
toxicity caused by the repeat in isolation also suggests inherent toxicity of the CGG repeat, even 
outside of the FMR1 gene.  Handa et al founds that expressing a CGG repeat without FMRP still 
is toxic to human cell lines (Handa, 2005).  Similarly, expressing repeat CGG RNA is 
ommatidial cells leads to degeneration in drosophila eyes, with dsFMRP still being expressed at 
regular levels (Jin, 2003).  A number of proteins have been implicated as potentially sequestered 
by CGG RNA repeats.  The evidence for their having a role in toxicity is thus: A number of 
specific proteins bind avidly to the RNA repeats. Two in particular, Pur α and  heterogeneous 
nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1), are capable of partially rescuing CGG repeat 
associated toxicity when overexpressed in the same model system.  Other proteins, including the 
CUG triplet repeat RNA-binding protein 1 (CUGBP1), and Src-associated substrate during 
mitosis of 68 kDa (Sam68), do not interact directly with the RNA but are found in inclusions in 
patients (Garcia-Arocena 2010 and Sellier 2010).  The overexpression of proteins such as Pur a 
and hnRNP A2 leading to rescue suggest that the loss of function of specific RNA binding 
proteins is the main component of toxicity of FXTAS, through mechanisms such as loss of 
chaperone activity or altered RNA maturation due to altered RNA splicing activity (Jin 2007 and 
Sofola 2007).   
The caveat to this evidence in favor of sequestration, however, is the fact that many of the 
proteins that successfully rescue FXTAS phenotype when overexpressed also have general 
neuroprotective effects, and could thus be compensating for some other mechanism. For example 
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the overexpression of Hsp70 and Pur a contribute significantly to rescue when present in 
abundance in the cells (Jin 2003).  This could be evidence that, rather than sequestration, the 
CGG RNA could serve as a trigger for some other mechanism that benefits from the presence of 
heightened cellular regulation. However, despite these alternative mechanisms, the RNA gain of 
function hypothesis is the prevailing model for FXTAS pathogenesis. 
 
Drosophila Models of FXTAS 
Our lab uses a Drosophila model of CGG repeat mediated neurodegeneration developed 
by the Jin lab, and characterized in their 2003 Neuron paper.  Flies were generated by placing a 
human FMR1 DNA fragment from a premutation carrier upstream of EGFP.  This sequence 
contains 90 CGG repeats, with AGG triplets at repeat 10 and 20, followed by a roughly 200 base 
pair flanking sequence.  Importantly, the transcriptional start site occurs before the CGG repeat, 
and the only AUG translational start site is downstream of the repeat.  These flies were initially 
generated to  determine whether the repeat in isolation from the rest of the FMR1 transcript 
could elicit toxicity.   
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In order to observe the impact of the CGG repeat on neuronal viability, we and other researchers 
have utilized the GAL4/UAS system to direct expression of the repeats exclusively in oomatidial 
cells in the fly eye.  The CGG-GFP sequence was placed under control of the UAS promoter.   
These flies were then crossed to a second line of flies that express Gal4 under a GMR promoter 
that is specific to retinal cells; thus, the CGG repeat was only expressed within the retinal cells 
and neurodegeneration would be visible in the animals’ eyes.  Lines were also created in which 
the repeat expression was weaker, as well as only 60 CGG repeats rather than 90.  In addition, 
the repeat was also expressed under the control of a number of other promoters, including the 
ELAV promoter, in which expression is pan-neuronal; the Act5C promoter, resulting in 
ubiquitous expression; and the dpp promoter, which expressed the transgene around the 
boundaries of the imaginal discs and epithelial cells. 
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The researchers found that the rCGG transgene elicited neurodegeneration that was dosage and 
repeat length dependent.  For moderately expressed CGG60, no toxic effects were observed, 
whereas in strongly expressed CGG60, a mild rough eye phenotype when expression was limited 
to the oomatidia and reduced viability when expressed ubiquitously.  Moderately expressed 
CGG90 also resulted in a rough eye phenotype and reduced viability, and the strongly expressed 
CGG90 showed a very severe rough eye phenotype and larval lethality.   
In flies where the transgene was activated after eclosion the CGG repeat elicited progressive 
degeneration, especially at higher temperatures.  They also accumulated ubiquitinated inclusions, 
much like in human cases of FXTAS; these inclusions were found to co-localize with Hsp70, a 
chaperone protein.  From this experiment, the authors concluded that the CGG RNA was the 
toxic force driving FXTAS pathogenesis.  Because they saw neurodegeneration through this 
model, they concluded that RNA enough was sufficient to induce toxicity.  They saw this as 
support for an RNA gain of function mechanisms, in which inclusions, such as the Hsp70 
aggregates that they characterized, are generated by binding to RNA, which sequesters the 
proteins with which it interacts.     
 
 
Repeat Associated Non-ATG Translation 
Translational initiation is highly organized event whereby an 80S ribosomal subunit is assembled 
over a specific start codon (usually AUG) on a messenger RNA (Sonnenberg 2009).  In 
eukaryotes, initiation factors (eIFs) bind to the mRNA’s m7G cap, thus activating the mRNA for 
the preinitiation complex (PIC) binding (Sonnenberg, 2009).  The PIC is then able to scan the 
mRNA for an AUG codon in order to begin translation (Sonnenberg, 2009).   While there have 
 13 
been cases discovered of non-AUG initiated translation, in which codons similar to AUG (such 
as ACG, CUG, or GUG) are able to begin translation by being confused for an AUG, such 
occurrences are still dependent upon the binding of a methionine tRNA to begin transcription 
(Touriol 2003).   
Recently, however, exciting new evidence has emerged suggesting that, in cases of repeat 
expansions, translation can be initiated by the repeat itself, through a process called repeat-
associated non-ATG (RAN) translation.  This process was first characterized in a paper by Zu et 
al., in which they discovered that mutating the ATG initiation codon just before the 5’ CAG 
expansion did not affect the production of the aberrant polyglutamine protein (Zu 2011).  To 
study this further, they inserted a 6X STOP codon cassette (two stops in each frame) just 
upstream of a CAG repeat and placed three different tags C-terminal to the repeat to monitor 
protein expression in all frames.  Expression of this construct led to production of  proteins in all 
three reading frames in the absence of an AUG start codon.  These products  were not present in 
untransfected cells or in cells treated with cyclohexamide, suggesting that translation is required 
for the production of these proteins (Zu 2011).  Immunofluorescence indicated that all three 
aberrant proteins could be produced in the same cell (Zu 2011).  The group used a variety of 
methods, including mass spectrometry, generation of novel antibodies, immunoprecipitation, and 
C-terminal epitope tags, to confirm the identity and presence of the homopolymeric proteins (Zu 
2011).  Mass spectrometry confirmed that no proteins containing the N-terminal methionine 
were detected, suggesting either that translation occurs without incorporation of the initiating 
methionine, or that it is rapidly removed following translation.  Transcripts from these  
constructs  co-sedimented with ribosomes, and they confirmed that no splicing occurred on these 
transcripts to insert an AUG start.  Variation of CAG expansion length showed that a certain 
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length was required to elicit RAN translation and the comparison between CAG expansions and 
CAA expansions indicate that RAN translation is facilitated by hairpin structures, as CAG forms 
a hairpin and participates in RAN translation, but CAA, which does not form a hairpin structure, 
does not result in RAN translation products.   
To begin to test the relevance of this mechanism to disease pathogenesis, Zu et al looked 
at whether expressing the homopolymeric proteins elicited co-expression of apoptosis proteins in 
transfected cells. In cells expressing all three RAN translation products, they found that 
significant increases in annexin-V, indicating an upregulation of apoptosis in these cells.  
Through using an antibody made to detect the predicted RAN translation products, researchers 
found significant staining in in vivo models of SCA8 and DM1 and in DM1 patient derived 
tissues.  Ultimately, this research suggests the possibility that these proteins could participate in 
disease pathogenesis of disorders commonly thought to be solely determined by an RNA gain of 
function mechanism. 
Recently, two further studies were published extended these initial findings by Zu et al to 
other repeat expansion diseases.  The newly discovered C9ORF72 GGGGCC hexanucleotide 
repeat, implicated in FTD and ALS, was investigated as possibly undergoing RAN translation.  
As hairpins formed from repeats are more likely to undergo RAN translation, investigators 
modeled the secondary structure of the hexanucleotide repeat, finding that it is energetically 
favorable for this repeat to form a hairpin structure (Ash 2013, and Mori 2013).  This lead the 
researchers to generate antibodies for all of the possible RAN translation products from such a 
repeat, which would produce three different two amino acid alternating copolymers--glycine-
alanine, glycine-arginine, and glycine-proline (Ash 2013).  Impressively, these antibodies 
detected RAN translation products through slot blot and immunohistochemical analysis in 
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samples from C9orf72 ALS and FTD patients, but not from other ALS/FTD patients or controls.  
While the contribution of these RAN translation products to toxicity is not yet completely 
defined, the presence of these aberrant protein products does seem to be a novel 
neuropathological feature in this disease.  This study raises a number of interesting questions, 
particularly in regards to how toxic these products are, and how frequently they occur in 
pathogenesis of repeat expansion diseases.  As FXTAS is a disorder caused by a repeat 
expansion that is able to form a strong hairpin in mRNA form, it is possible that RAN translation 
could be occurring within those with FXTAS. 
 
Unpublished data from our group indicating the production of a RAN translation product 
in association with CGG repeats. 
Presence of a Higher Molecular Weight GFP product in CGG-GFP flies 
Shortly after obtaining the CGG90-GFP fly model from the Jin Lab, Dr. Todd noted that 
the GFP expressed in these flies formed aggregates when expressed.  This unexpected finding 
led to a series of studies demonstrating that CGG repeats can trigger RAN translation.  First, 
lysates from CGG-GFP flies demonstrate the presence of a higher molecular weight GFP 
product.  While the expected molecular weight of GFP protein is around 25 kDa, in the FXTAS 
model flies there was a species observed through immunoblotting against GFP that was of a 
higher molecular weight, at about 37 kDa.  Mass spectrometry performed on this higher MW 
GFP band indicated that it was a fusion protein of GFP and sequences within the FMR1 5’UTR.  
The reading frame and size of the band indicated that the repeat was being translated into a 
polyglycine protein, strongly suggesting that it is a RAN translation product, as there are no 
upstream translational starts in frame with polyglycine. 
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Further experiments were done to show that without the CGG repeat expansion, the FMRpolyG 
protein does not form.  Deletions of repeat stretches in the 5’UTR severely decreased and even 
abolished production of the RAN translation product (data not shown).  This indicates that 
translation of this protein initiates at a non-AUG codon within the CGG repeat, possibly through 




Presence of aberrant translation product in FXTAS model mice  
In mouse model systems, our lab uses two strains to model FXTAS--a mouse line we refer to as 
the NIH mice, and another we call the Dutch line.  Each line replicates certain behavior and 
molecular aspects of FXTAS, but interestingly only the Dutch line produces the RAN translation 
product. When probed by another antibody created to recognize the higher molecular weight 
product (which we named FMRpolyG) sections of cortex from the two different mouse lines 
show very different staining patterns, with the Dutch line showing intranuclear inclusions, but 
with little staining in the NIH mouse line.                
This discrepancy between the two models of the same disease can be explained through the 
aberrant translation product hypothesis, through examining the sequences of the two lines.    
While the both lines exhibit a CGG of premutation length that has been knocked in to the mouse 
FMR1 gene, the NIH line begins with a translational stop codon (TAA) that is 18 base pairs 
upstream of the beginning of the repeat sequence, which is predicted to abolish the production of 
the HMW product.  Indeed, when the NIH mouse sequence just proximal to the repeat is placed 
upstream of the GGC repeat sequence in cell culture lines, it abolishes the production of the 
polyglycine protein.  This finding provides evidence for the presence of a RAN translation 






Aberrant protein present in FXTAS patients and FXTAS model systems 
To determine whether or not the aberrant polyglycine protein is produced in human cases of 
FXTAS, a monoclonal antibody (2C13) was developed based on the predicted sequence of the 
human aberrant product.  This antibody, which was tested for specificity based on its ability to 
recognize a recombinant protein generated in bacteria, was tested on western blots of cerebellar 
lysates from FXTAS and control brain samples.  The predicted protein product from the 
aberrantly translated product is predicted to be approximately 11.5 kDa, with an N-terminal 
polyglycine stretch and a 42 amino acid stretch out of frame with the FMR1 protein coding 
region (Todd, unpublished data).  In FXTAS brain lysates, a 12 kDa protein was observed by the 
2C13 antibody that was not observed in the control lysates.    When cerebellar sections were 
immunostained with this antibody, the FXTAS sections exhibited perinuclear aggregates, while 
control tissue did not.  FXTAS sections also consistently exhibited ubiquitinated intranuclear 





The work that the Todd lab and I have done thus far indicate the presence of a RAN translation 
protein product in various models of FXTAS.  In flies, lysates taken from ommatidial cells 
expressing the CGG100-GFP transgene show the presence of a higher molecular weight GFP 
product when probed for GFP protein, as well as significant GFP inclusion formation in 
ommatidial cells.  The mass spectrometry data for this protein indicates that it is a fusion protein 
between GFP and a polyglycine (GGC) protein.  We found that staining FXTAS mouse and 
human tissue with antibodies created against this FMRpolyG protein showed the presence of 
inclusions positive for this protein, which were not present within control tissue.   
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Given the presence of this protein within FXTAS model systems and patients but not in control 
tissue, it would seem that it is part of FXTAS pathogenesis.  The central question of this thesis is 
whether this aberrantly produced FMRpolyG protein is able to produce toxicity. 
Based on the prevalence of this protein across all different models of FXTAS, as well as the 
numerous other neurodegenerative diseases with protein-induced toxicity, I hypothesized that 
production of this protein does lead to toxicity.  To test this, I used a number of parameters to 
characterize fly lines expressing CGG RNA and the FMRpolyG protein at different levels, in 





















Drosophila Melanogaster lines were crossed and maintained at 25 degrees on standard food 
unless otherwise indicated.  All crosses set up between the transgene and the GMR-GAL4 driver 
were done at 30 degrees.   
  
Generation of fly lines 
All fly constructs were derived from cell culture plasmids with the replacement of (CGG)88 with 
(CGG)100 from FXTAS patient fibroblast cell genomic DNA, and were inserted into restriction 
sites BglII and XbaI of a pUAST vector. Transgenic flies were made by standard p-element 
insertion (The Bestgene Inc., Chino Hills, CA), and were mapped and balanced with standard 
genetic techniques.  Briefly, flies were crossed to double balancer (Cyo/+; TM3/+) flies first, and 
flies with both of the balancers and transgene were selected to breed.  Following this cross, 
chromosomal location of the transgene was determined based on with which balancer it 
migrated.  Flies were maintained with standard food at 25 degrees (Todd, 2013).   Transgenes 
used are as follows (also see Table 1): 
1) 5’UTR: CGG100 repeat followed by GFP open reading frame.  The GFP translational start 
codon is in-frame with the GGC polyglycine. 
2) 5’ATG: An introduced ATG codon followed by the CGG100 repeat and in-frame GFP 
open reading frame. 
3) 5’ Stop: A translational stop in the 5’UTR just before the pure CGG repeat.  Following 
this is the GFP reading frame. 
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4) 3’UTR: The coding sequence for GFP, followed by a translational stop. After the stop, in 




Groups of twenty 1-2 day old adult flies were anesthetized using C02 and decapitated.  Total 
RNA was then extracted from the fly heads through a previously described Trizol protocol (Todd 
2010).  Briefly, tissues were homogenized in 1 mL of Trizol per 50 to 100 mg of tissue.  0.2 mL 
of chloroform was then added per 1 mL Trizol used for the phase separation step.  Samples were 
shaken vigorously for 20 seconds and then incubated at room temperature for 2 to 3 minutes.  
Samples were centrifuged at 12,000 x g for 15 minutes at 4 degrees.  Following centrifugation, 
the solution separates into a bottom red, phenol-chloroform phase, an interphase, and an upper, 
clear aqueous phase, which contains the RNA.  The aqueous phase was then removed and placed 
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into another centrifugation tube.  To precipitate, the aqueous phase was mixed with 0.5 mL 
isopropanol per 1 mL Trizol reagent used.  This solution was incubated for 10 minutes at room 
temperature, followed by centrifugation at 4 degrees, producing an RNA pellet.  Finally, the 
pellet was washed with 1 mL 75% ethanol, dried to isolate pellet, and then the RNA was 
resuspended and quantified. 
 
RT PCR 
Following RNA extraction, RT PCR was performed in order to create cDNA to be used in QPCR 
reactions.  For this, the iScript (Bio-Rad) cDNA synthesis protocol was used.  Briefly, 500ng of 
RNA was mixed with  4 uL of 5X mix, 2uL of Oligo dT primer, a 1 uL of iScript reverse 
transcriptase and DEPC treated water to 20 uL total.  This was then mixed lightly and run 
through the iScript cDNA synthesis PCR program  The iScript cDNA PCR protocol is as 
follows: 5 minutes at 25 degrees, 42 degrees for 30 minutes, then 5 minutes at 85 degrees for 
enzyme inactivation.    
 
QPCR analysis 
The resulting cDNA was subjected to real-time PCR analysis with gene 
specific primers as follows: eGFP: (Forward: 5’-TCTTCTTCAAGGACGACGGCAACTAC- 
3’, Reverse: 5’-GTACTCCAGCTTGTGCCCCAGGATGT-3’), RPL32: (Forward: 
5’-GTTGTGCACCAGGAACTTCTTGAATCCG-3’, Reverse: 5’- 
CTTCCAGCTTCAAGATGACCATCCGC-3’).  PCR analysis was performed using the iQ 
SYBR Green Supermix in a myiQ Single Color RTPCR system (BioRad). All runs included a 
standard dilution curve representing at least 2x and 0.01X the RNA concentration utilized for all 
primer sets to ensure linearity. Further, equivalent efficiency of individual primer sets was 
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confirmed prior to data analysis. The levels of (CGG)100-containing eGFP mRNA were 
normalized to RPL32 mRNA for each sample run and expressed as a ratio of levels found to 
individual lines (fold control expression). All samples were run in triplicate and all data represent 
at least three independent experiments (Todd, 2013).  
  
Phenotype assessment 
Phenotype severity was assessed using a validated scale of neurodegeneration seen in fly eyes 
(Pandey, 2007).  The scale assigns one point based on each disturbance found in ommatidial 
structure and organization, bristle organization, ommatidial fusion and pitting, de-pigmentation, 
and scarring (See Table 2).  When degeneration occurred in more than 5% of the eye, 2 extra 
points were given; when present in over 50% of the eye, 4 points were given.  Typically >50 flies 
were scored, and averages were created of all of the genotypes so that they could be graphed and 





Fly Eye Imaging 
Young flies were anesthetized with CO2 or frozen.  At 80X magnification, pictures of eyes were 
taken with a Leica MZ APO microscope, and captured with Leica DFL320 digital camera.  For 
fluorescent image capture of GFP aggregates, flies were frozen and placed on a glass coverslip.  
An inverted Olympus 1X71 scope was used to take images by epifluorescence, and images were 
then processed in Slidebook 4.0 software. 
 
Fly Histology/Immunohistology 
1-2 day old flies were taken, anesthetized and decapitated, and their heads were immediately 
frozen in OCT media.  They were then cryosectioned transversely.  The sections were post-fixed 
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for 15 minutes in 4% paraformaldehyde, permeabilized with 0.1% triton-X, and processed for 
immunohistochemistry as previously described (Pandey 2007).  Antibodies were not necessary to 
visualize GFP in the CGG90-EGFP flies.  For ubiquitin visualization, a Millipore antibody was 
used at 1:250 dilution.     
 
Western Blot Analysis 
Western blots were prepared as previously described and developed on film (Todd and Mack 
2000).  Briefly,  protein was extracted by homogenizing fly heads in RIPA buffer with protease 
inhibitors.  Equal amounts were then boiled with 4X SDS Dye and run on a 12% SDS 
polyacrylamide gel.  After PVDF transfer at 30 amps for 12 hours at room temperature, blots 
were incubated with antibodies to GFP(1:1000) and tubulin (1:5000).   
 
Viability assessments 
Analysis of relative eclosion rates were performed as previously described (Lanson et al., 2011). 
Each transgene was balanced over a marker chromosome (CyO). If the transgene elicited no 
toxicity, then 50% of progeny should have the CyO marker and 50% express the transgene. >200 
flies of each genotype were scored over multiple crosses. The relative % progeny carrying the 
transgene were expressed as a % of total eclosed flies. These numbers were then compared using 








Creation of novel FXTAS fly lines 
Four new fly lines were generated with the goal of decoupling the RNA and protein toxicity from 
one another.  A first line was created in which the GGC100 stretch was followed by the coding 
region for EGFP, with the translational start site directly preceding the EGFP ORF; this strain 
should produce both a GFP protein and a RAN translated polyglycine-GFP fusion protein.  The 
second transgene was created to produce high translational expression of the polyglycine protein; 
its sequence is ATG-FLAG-GCC100-GFP, with the ATG driving translation of the GGC repeat in 
frame with the GFP.  Next, a line was created in which the GGC100 stretch is placed in the 
3’UTR of GFP; GFP-STOP-GGC100.  Finally, a stop codon was inserted 5’ of the GGC repeat, to 
prevent RAN translation of the polyglycine product.  The purpose of these final lines is to ensure 
that, while the CGG repeat mRNA is present, its protein product will not be produced, thus 
providing a test for whether or not the aberrant protein product can be implicated in FXTAS 
toxicity.  To demonstrate this empirically, we transfected cells with a construct expressing GFP-
STOP-GGC100 with a FLAG tag after the repeat.  Expression of this construct was compared to 
vectors expressing the other constructs described above.  Serial probing of these blots with 
antibodies to GFP, FLAG and Actin revealed the presence of a FLAG positive band only in 
constructs expressing the ATG-FLAG CGG-GFP construct, despite high level expression of the 





In order to measure neurodegeneration in these lines, we took advantage of the UAS/GAL4 
system.  The transgenes described above were placed under the control of the UAS promoter, 
and their expression was directed to the by placing GAL4 under the GMR promoter, which is 
retinal-cell specific.  This allows us to visualize degeneration through retinal cell death and 
disorganization.  The fly lines were bred and maintained at 30 degrees.   
 
Quantification of GFP mRNA 
To determine the levels of GFP mRNA transcript produced by each of the three lines, cDNA was 
synthesized via RT-PCR, and the levels of transcript were quantified through QPCR.    While 
placing the CGG expansion in the 5’ UTR moderately increased transcript, we chose lines to 
analyze to ensure that the level of transcript production was as close as possible.   While the 
placement of the CGG repeat in the 5’ UTR produced more transcript, the two lines with the 
repeat located in the 5’ UTR produced less translated GFP.  
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RAN translation product is present in FXTAS model lines 
To assess whether or not these new lines were undergoing RAN translation, we probed the flies 
for the presence of a higher molecular weight (HMW) GFP fusion protein found in cell lines.  
For this, we performed a western blot analysis on proteins extracted from fly heads.  The blot 
was serially probed first with an antibody for GFP and then secondarily with an antibody to 
Tubulin and developed using standard film.   As anticipated based on previous studies, CGG100-
EGFP expressing flies demonstrated two products by western blot- one correlating with 
translational initiation at the AUG for GFP and one correlating with RAN translational initiation 
5’ to the repeat.  In contrast, in flies where the CGG repeat was placed in the 3’UTR, Only the 
band correlating with AUG initiation at GFP was observed.  In flies where an AUG in an 
appropriate Kozak sequence was inserted upstream of the repeat, we observe production of a 
larger GFP-polyglycine fusion protein, consistent with the inclusion of the FLAG tag and some 
additional sequence preceding the repeat.  Interestingly, usage of this upstream AUG largely 
precludes initiation at the repeat by RAN translation or initiation at the canonical AUG for GFP.  
These results indicate that aberrant translation is supported in drosophila and suggests that it is at 




Transgenic lines producing the aberrant fusion protein showed neurodegeneration 
Because the transgene was directed to retinal cells specifically, neurodegeneration was 
quantifiable through direct observation of the fly eyes.  Each eye was assigned a score based on 
the levels of cell death, ommatidial structure, and bristle arrangement, with higher scores 
indicating more degeneration and toxicity. 
The 5’ATG lines exhibited significant degeneration of the retinal cells, indicating that the high 
expression of the fusion protein was highly toxic.  The 5’UTR line showed moderate 
degeneration, while the 5’Stop and 3’UTR showed little evidence of degeneration.  At least 50 
flies from each line were assigned scores, which were averaged to reflect a typical score for each 
line.  These scores reflect the levels of degeneration observed 
visually.  These results suggest that production of the polyglycine protein correlates significantly 




Inclusion formation  
A hallmark of human FXTAS and animal models of FXTAS is the presence of intranuclear 
inclusions within affected areas. To determine whether or not these new fly lines replicated this 
aspect of the disease, we examined the eyes for GFP inclusions both through transverse sections 
and confocal imaging, and whole-eye imaging with epifluorescence.  Epifluorescence imaging 
showed that the number of GFP + inclusions directly correlated with the amount of HMW 
produced.  The 5’ATG line produced a large number of GFP punctate inclusions, and 5’UTR 
produced a moderate amount, while the 5’Stop and 3’UTR produced none at all.  In order to 
determine whether or not these GFP inclusions colocalize with ubiquitin, similar to the ubiquitin-
positive inclusions in FXTAS, we performed a colocalization with a ubiquitin antibody on 
transverse slices of retinal tissue, and analyzed them through confocal imaging.  In both 5’ATG 
and 5’UTR, the vast majority of GFP inclusions colocalized with ubiquitin. In the 3’UTR and 
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5’Stop lines, the diffuse GFP does not aggregate and form inclusions.  This suggests that the 
GFP itself does not aggregate; rather, the addition made to it to produce the HMW GFP species 
contains is what has the propensity for aggregation.  We believe that this aggregate-prone species 





As a second readout for repeat associated toxicity, we determined whether or not ubiquitous 
expression of the three different transgenes had an impact on fly viability.  We crossed flies with 
transgenes under control of the UAS promoter to those expressing act5-GAL4, which results in 
ubiquitous expression of the transgene.  For each line, the transgene was balanced over the Cyo 
balancer.  If the transgene elicits no toxicity, 50% of the resulting progeny should have the Cyo 
marker, and 50% express the transgene. Through this, we found that placing the CGG repeat in 
the 5’ UTR resulted in a decrease in the percentage of progeny produced with the transgene, 
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indicating that the transgene conferred increased toxicity to the flies and thus decreased viability.  
Placing the ATG in front of the CGG repeat in the 5’ UTR enhanced toxicity and decreased 
viability, while the line in which the CGG repeat was in the 3’ UTR following a translational 
stop experienced no decreased viability.  This provides more evidence that producing the 
polyglycine protein results in enhanced toxicity of the CGG repeat. 
 
 
Rapamycin treatment is ineffective in clearance of the FMRpolyG protein 
Numerous studied have suggested that rapamycin has neuroprotective effects in a number of 
neurodegenerative disease models, through its ability to inhibit the mTOR pathway (Berger, 
2006).  The prevailing theory regarding its ability to rescue neurodegeneration is that it 
stimulates the autophagy pathway, thus clearing toxic protein aggregates.  We thus decided to 
test rapamycin’s effect on flies with a CGG100-GFP transgene (analogous to the 5’UTR line).  
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CGG100-GFP and GMR-GFP flies were bred and eclosed on food with or without rapamycin at 
1.0 uM concentration at 25 degrees.  Protein lysates were probed for the presence of the higher 
molecular weight GFP protein, and fly eyes were imaged and scored as described above.  From 
the western blot, we found that there was no decrease in higher molecular weight product as we 
had expected.  There was also no significant difference in eye phenotype between CGG100-GFP 
lines with or without rapamycin.  Thus, rapamycin seemed ineffective in reducing aberrant 
protein production and aggregation, as well as ineffective on rescuing the degenerative 
phenotype.      









The results provided above challenge the predominant view of FXTAS toxicity; namely, that it is 
strictly caused by an RNA gain of function mechanism.  The fly lines we generated successfully 
decouple the production of CGG RNA from the production of CGG RAN translated protein, as 
well as provide a model in which the polyglycine fusion protein is definitively expressed.  Our 
model of the three lines suggests that the difference in sequence leads to the production of 
different proteins--in the case of the line with the repeat in the 3’UTR directly after a 
translational stop, no polyglycine-GFP fusion protein is produced.  When the ATG drives 
production of the CGG repeat, virtually the only species produced is the higher molecular weight 
fusion protein.  In the more traditional FXTAS model, however, in which the CGG is placed in 
the 5’ UTR followed by an ATG translational start, we propose that a mix of these two species is 
present.  This last model seems to be relatively representative of the way in which FXTAS works 
in mammalian cells. 
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 Importantly, through characterization of these flies, we discovered striking differences 
between toxicity of the different lines.  The differential levels of toxicity followed the predicted 
levels of HMW fusion protein produced, with high expression resulting in severe degeneration, 
modest expression leading to moderate degeneration, and no expression resulting in no 
degeneration.  This shows that, at in drosophila, the aberrantly expressed protein is able to 
significantly mediate toxicity.   
Similarly, it also seems that production of CGG mRNA in these lines is not as crucial to 
toxicity as the RNA gain of function model would suggest. In addition to the differential levels 
of degeneration, viability data also indicates that somehow the protein produced enhances the 
toxicity of the repeat, as CGG RNA expressed ubiquitously did not significantly decrease 
viability, while ubiquitous expression of the RAN translation product did.  This data is the first to 
provide evidence of a direct role for RAN translation in FXTAS pathogenesis, as well as 
dissociate CGG repeat RNA from possible polyglycine protein production. 
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 Following the establishment of the toxicity of this protein, one of the next tasks at hand is 
to determine what about this protein is toxic.  In many neurodegenerative disorders that involve 
the formation of aggregations that appear to be toxic, impairment of the UPS is implicated in 
toxicity, along with cellular/oxidative stress.  As neurons are particularly vulnerable to cellular 
stress and disruption to homeostasis, mechanisms that aim to maintain normalcy within the cells, 
such as autophagy and the UPS, are crucial, and often implicated in neuronal disease and 
dysfunction (Wong 2010).  With this in mind, it would be valuable to further investigate the role 
that protein quality control and degradation pathways play in FXTAS.  While in many diseases 
upregulation of protein degradation systems, such as upregulation of autophagy through 
treatment with  rapamycin, has been shown to be effective in attenuating the toxicity of 
aggregative species in animal models.  Indeed, previous studies and work in our own lab 
demonstrates that overexpression of specific protein chaparones, such as HSP-70, partially 
alleviates CGG repeat associated toxicity.  This appears to be a Ubiquitin proteasome specific 
effect, however, as our preliminary data in FXTAS suggests that genetic impairment of 
autophagic pathways does not exacerbate CGG associated toxicity and Rapamycin treatment is 
not effective in reducing toxicity (Todd 2010).  Further investigation into this area might be 
productive in determining how the RAN translation products produce toxicity.  If there is 
somehow an impairment to the autophagy system, induction of autophagy through rapamycin 
would not have an effect on inclusion toxicity, and may even increase it, as an increase in 
autophagosome formation without clearance results in further accumulation of proteins and 
cellular stress (Bove 2011).  Investigating whether or not the presence of these aberrantly 
translated proteins somehow impair one of the many pathways neurons use to maintain 
homeostasis could be a fruitful area for discovering the mechanism of toxicity. 
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Determining whether or not the presence of the protein causes an increase in cellular 
stress may also provide insight into its toxicity.  There are many ways in which a cell can 
respond to stress, and observing cells expressing these repeat proteins for specific signs of 
cellular stress may help determine which pathways are disrupted or activated by the presence of 
the polyglycine/polyalanine proteins.  For example, looking for an upregulation of apoptotic 
markers or heat shock proteins could help determine exactly what mechanisms are at work to 
cause degeneration in these flies.  Comparing changes in our 5’ATG line and the 3’UTR line 
could be particularly insightful, as it would help to elucidate what mechanisms are at work when 
proteins are produced in comparison simply to repeat RNA.  These comparisons are also useful 
in that they could help to determine the relative contribution of repeat RNA to FXTAS; while 
this data provides evidence of the toxic nature of an aberrant RAN translation product, there is 
still a significant amount of data discussed in the introduction that implicates CGG RNA in a 
gain of function toxicity mechanism.  It has been shown that this mRNA is able to sequester 
proteins that will very likely have downstream impacts on normal cellular processing.  Thus, 
there are still many reasons to believe that RNA plays some part in toxicity; the difficult part will 
be delineating the roles of the two toxic species, and the extent to which both of them contribute 
to toxicity. 
  The concept of RAN translation itself is a very new one, only brought to the attention of 
the scientific community in 2010 by Zu et al.  Because of its newness, few researchers studying 
trinucleotide expansion diseases have really explored it as an option as a possible aspect of 
pathogenesis.  There are a wide range of repeat expansion diseases for which this mechanism 
might be applicable, and future research will need to be done to explore this as a possibility.  It 
would be extremely interesting if this method of translation turns out to be a common occurrence 
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in neurodegenerative diseases, especially if the proteins produced from it play a role in toxicity 
in other diseases as well.  Perhaps in the future, treatments could be proposed based on inhibiting 
this mechanism.  As RAN translation appears to be dependent on the formation of an mRNA 
hairpin, this may prove to be a target of therapeutic research.  In addition to being an important 
aspect of disease, it is a distinct possibility that RAN translation may have other roles within 
cells even in non-disease states, which may provide further insight into the the way in which 
ribosomes and other translational machinery works.  
Ultimately, this data presents a new aspect of FXTAS pathology, and is only a small 
aspect of our lab’s larger body of work that suggests that the canonical description of FXTAS as 
solely an RNA gain of function disorder is only one aspect of the disease.  We will continue to 
examine this aspect of the disease and how it contributes to our understanding of FXTAS and 
neurodegenerative disorders as a whole.  Hopefully, the research that has been done and will be 
done in the future by our lab will be informative to the neurodegenerative field as a whole, and 
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